Numbers in Italics Indicate Figures; Altman Splint 396 Anthelmintics 55–6 Numbers in Bold Indicate Boxes

Total Page:16

File Type:pdf, Size:1020Kb

Numbers in Italics Indicate Figures; Altman Splint 396 Anthelmintics 55–6 Numbers in Bold Indicate Boxes Index Index Numbers in italics indicate figures; Altman splint 396 Anthelmintics 55–6 numbers in bold indicate boxes. Aluminium hydroxide 61 Antiarrhythmic drugs 60 Aminoglycosides 54 Antibacterial drugs 54 Amitraz 57 Antibiotics, definition 54 ABC mnemonic 109, 111, 287 Amlodipine 60 Anticoagulants 206 ABCD mnemonic 305 Ammonium urate crystals 219 Antidiarrhoeal agents 61 Abdomen Amoxicillin 54 Antidotes 123 bandaging 388, 389 Amphotericin B 55 Antiemetics 61 counterpressure in CPCR 110 Ampicillin 54 Antiepileptic drugs 58 emergency examination 120 Anaemia 153–4 Antifungal drugs 54–5 examination 142 Anaesthesia Anti-inflammatory drugs 57–8 radiographic positioning 253 accidents and emergencies 304–5 Antimicrobial drugs 54–5 Abrasions 375 anaesthetic machine 269–71 Antineoplastic drugs 55 Abscesses 346–7 analgesics 284, 293–6 Antiparasitic agents 42–3, 55–7 lung 352 for birds 312–14 Antiprotozoal drugs 55 prostatic 364 circuits 271–83 Antiseptics 78–9 ACE inhibitors 60 gas flow rate calculation 275 Antitussives 60, 61 Acepromazine 284 gases 289–91 Antiviral drugs 55 combinations 284, 307 health and safety 291 Aortic stenosis 150 Acetazolamide 64 induction 285–8 APL (adjustable pressure-limiting) valve Acid–base imbalances 133, 327 local 292 272 Activated charcoal 123 maintenance 288–91 Humphrey 279–280, 283 Active exercise 195, 199 monitoring 297–303 IPPV 283 Acute heart failure 151–2 neuroleptanalgesia 284 Apnoea 299, 304 Acute renal failure 160–1 neuromuscular blocking agents 293 Apomorphine 61 Acute respiratory failure 148–9 pollution 291 Appetite 89 Addison’s disease see premedication 283, 284, 285 stimulation 184 Hypoadrenocorticism for radiography 241 Appointments 11 Adjuvants 59 recovery 302 Appraisals 1–2 Admitting patients 48–9 for reptiles 310–12 Archaeopsylla erinacei 40 Adrenaline 106, 110, 124, 304 role of the VN 4 Arrhythmia 117 Advice see Client advice scavenging 291 Arterial blood gases 115 Ageing 176–7 sedatives 284, 285 Arteriodilators 60 Aggressive animals, handling 92, 93 for small mammals 305–10 Arthritis 172–3 Aggressive clients 13 stages 296–7 Arthrocentesis 221 Aglepristone 63 Anaesthetics Arthrodesis 345 Airway combinations 287 Arthrography 257 emergencies 107, 109, 111 intravenous 286, 289 Arthroplasty 345 extubation 288 local 292, 293, 296 Arthroscopy 345 intubation 287–8 volatile (inhalation) 289, 290 Arthrotomy 345 in birds 313 (see also specific agents) Artificial tears 64, 302 in rabbits 308 Anal furunculosis 359 Asepsis 107, 317–18 obstruction 116, 304, 351 Anal sac impaction 359 (see also Sterilization) (see also Respiratory system, Analgesia 293–4 Aspirin 295 Trachea) Analgesics toxicity in cats 58 Alanine aminotransferase (ALT), NSAIDs 293, 295–6 Assisted feeding see Feeding/diet abnormalities 215 opioids 293, 294–5 Atipamezole 268, 304, 307 Albumin, abnormalities 215 as premedicants 285 Atopic dermatitis 176 Alfaxalone 286 for reptiles 311 Atracurium 293 Alfaxalone/alfadalone 286, 311, 313 for small mammals 306–7 Atropine 64, 106, 110, 304 Alginate dressings 385 Angiocardiography 257 Aural haematoma 369, 370 Alimentary tract see Gastrointestinal Angiography 257 Autoclave 318 tract Animal wards 81–2 Automated analysers 208 Alkaline phosphatase (ALP), Anorectal disease 359 AVM-GSL drug classification 70, 71 abnormalities 215 Anorexia 16, 183 Avulsion 375 Allis tissue forceps 322 postoperative 338 Alopecia 175 Antacids 61 BSAVA Manual of Practical Veterinary Nursing. Edited by Elizabeth Mullineaux and Marie Jones. ©BSAVA 2007 399 Index Babesiosis 37 Body Cardiovascular system Bacteriology 226–7 brace 339 drugs acting on 59–60 Bain circuit 273, 276 fluids, sampling 221 emergency examination 116–18 Balanitis 363 language Care plans see Nursing process Bandages/bandaging in cats 89 Carprofen 65, 295, 306, 311 abdominal 388, 389 in dogs 89 Carpus, radiographic positioning 247 ear and head 387, 388 in humans 12 Cash payments 50 Ehmer sling 391–2, 393 temperature Castration 364–5 foot 390–1 abnormalities 87, 120–1 Casts 395–6 birds 394–5 during anaesthesia 300–1 removal 397 layers 384–5 measurement 86–7 Cat bite abscess, lancing 346–7 materials 386, 387 neonates 29 Cat ‘flu 144, 146 removal 397 normal values 86, 112, 142–3 Cataracts 368 restraint for 387 raising/lowering 1–2 Catheterization see Urinary Robert Jones 388–9 water 127 catheterization rules 387 Bodyweight and fluid loss 129 Catheters tail 392, 393 Bone plates and screws 341, 342 for bitches 192 thoracic 387–8, 389 Bone tumours 172 care 138 Velpeau sling 391, 392 Booster vaccinations 34, 36 for cats 192, 193 wing 394 Bordetella bronchiseptica 59, 143 emergency equipment 107 ‘Barbering’, rodents 201 Borrelia burgdorferi 143 intravenous insertion 137 Barium sulphate 254 Bosun whistle 271 over-the-needle 134 Barrier dressings 382, 386 Boyle’s bottle vaporizer 271 through-the-needle 135 Barrier nursing 83–4 Bradycardia 299, 304 Cats Basal energy requirement (BER) 188 Bradypnoea 88, 112, 299 airway intubation/extubation 288 Bathing Breeding see Reproduction anaesthetic combinations 287 before surgery 328 Bromohexine 61 aspirin toxicity 58 soiled patients 183 Bronchodilators 61 behaviour problems 15–16 Beds/bedding for elderly patients 179 Bronchography 257 blood Behaviour problems 15–16 Buffy coat 211 cells 215 (see also Demeanour) Bupivacaine 292 sampling 209 Benazepril 60, 62 Buprenorphine 295, 306, 311 typing 131 Benign prostatic hyperplasia 364 combinations 284 body language 89 Benzoyl peroxide 64 Burette 135 body temperature 86, 112, 141 Betamethasone 63, 64 Burns 121–2, 375 BUN 129 Bethanecol 62 Butorphanol 61, 295, 306, 311 capillary refill time 112 Bicarbonate, normal/abnormal values combinations 284, 287 castration 364 132 Butterfly needles 135 catheters 192, 193 Bilirubin, abnormalities 215 creatinine 129 Biochemical tests 215–16 drug administration 94 Biopsy Cabergoline 63 dystocia 124 liver 361 Cadavers electrolytes 132 sample submission 227 disposal 83 exercise 23 skin 226 for postmortem examination 227 handling 92–3 tumours 348 Caesarean operation 28–9, 366 infectious diseases 144, 145 Biotin, deficiency/excess 19 Calcium injection 94 Birds lice 41 air sac insufflation 314 abnormalities 132, 216 male see Tomcats anaesthesia 312–14 dietary, deficiency/excess 20 mammary tumours 367 assisted feeding 204 normal values 132 mating 25 bandaging 394–5 Calcium carbonate crystals 219 blood cells 215 Calcium channel blockers 60 mites 41 diseases 202–3 Calcium oxalate crystals 219 mucous membrane colour 112 ectoparasites 225 Calcium sensitizing drugs 60 muzzle 92 feeding advice 17 Calculations neutering 31 radiographic positioning 253 blood loss 301 paracetamol toxicity 58 respiratory system 312 drug doses 69–70 PCV 128–9 vagino-urethrography 256 fluid loss/requirements 127, 129 pulse rate 87, 112, 116, 141 Bisacodyl 61 gas cylinder contents 270 reproduction 23–4, 25, 26 Bitch gas flow rates 275 respiratory rate 88, 112, 141 catheters 192 VAT 51 restraining aids 92 oestrous cycle 23 water intake 178 signs of pain 294 puberty 23 Campylobacteriosis 147 taurine deficiency 20 urinary catheterization 194 Cancer see Tumours urinary catheterization 194 Blood Canine distemper 59, 227 urine output 90 biochemical abnormalities 215–16 Canine parvovirus 59, 143, 227 urine SG 129 donors 130–1 Cannulation, nasal 114, 115 vaccination 59 gas monitoring 115 Capillary refill time venepuncture 93 glucose curve 165 abnormalities 88 water intake 90 haemoglobin 211 during anaesthesia 300 (see also Kittens, Queens) MCHC 211 measurement 88, 117 Cefalexin 54 MCV 211 normal values 112, 117, 142 Centrifuges 208, 211 PCV 211, 212 Capnography 303 Cephalic venepuncture 93–4, 210 pressure 153, 303 Carbimazole 62 Cephalosporins 54 RBC 211 Carbohydrates, deficiency/excess 19 Cerclage wires 341, 342 samples Cardiac arrest 304, 305 Cerebrospinal fluid sampling 221 collection 209–10 Cardiac glycosides 60 Cheatle forceps 317 preparation 210–11 Cardiogenic shock 117, 118 Cheque payments 50 preservation 206 Cardiopulmonary arrest 109–11 Chest compression 110, 111 smears Cardiopulmonary resuscitation (CPR) Cheyletiella 41, 147, 222, 223, 224 examination 214, 215 307 parasitivorax 41, 174, 225 preparation 212–13 Cardiopulmonary–cerebral resuscitation yasguri 226 preservation 214 (CPCR) Chiari/Syringomyelia Scheme 26 transfusion 130–1 equipment 107 Chinchillas typing 131 procedure 109–10, 111 analgesics 306 WBC 214 team 106 body temperature 142 400 Index pulse 142 Control of Hazardous Waste (England Digoxin 60 reproductive parameters 24 and Wales) Regulations (HWR) 2005 Dilated cardiomyopathy 151 respiratory rate 142 82–3 Diltiazem 60 Chip and pin 51 Control of Substances Hazardous to Diphenhydramine 64 Chlamydophila 59, 144 Health (COSHH) Regulations 2002 Diphenoxylate 61 Chloramphenicol 54, 63 5, 6, 7 Dipstick analysis 218 Chlorhexidine 79, 328 Controlled drugs 71–2, 73 Dipylidium caninum 39, 56, 220 Chloroxylenol 78 Copper (dietary), deficiency/excess 20 Direct debit payments 51 Chlorpheniramine 64 Corneal reflex 300 Dirofilaria immitis 36 Chlortetracycline 63 Corneal surgery, NMBAs 293 Dirty wounds 375 Cholecystography 257 Corneal ulceration 368 Discharge of patients 49 Chondroitin 66 Corticosteroids 58 Disinfectants 78–9 Chronic heart failure 152–3 COSHH 5, 6, 7 Dispensary 79 Chronic pulmonary failure 149 Coughing 148 Distemper 143, 146 Chronic renal failure 62, 160–1 Coupage 196 Distichiasis 368 Chronic rhinitis 350 COX see Cyclooxygenase Distributive shock 118 Ciclosporin 64 CPCR see Cardiopulmonary–cerebral Diuretics 58, 60 Cimetidine 61 resuscitation Dobutamine 304
Recommended publications
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • University of Groningen Multi-Residue Analysis of Growth Promotors In
    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
    [Show full text]
  • Pharmaceutical and Veterinary Compounds and Metabolites
    PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer [email protected] LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al
    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Benign Prostate Hyperplasia
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk BENIGN PROSTATE HYPERPLASIA Author : Henry L’Eplattenier Categories : Vets Date : April 4, 2011 Henry L’Eplattenier considers this common condition in older dogs and discusses its symptoms and treatment THE prostate is the only major accessory sex gland in the dog. It is a bilobed structure that completely encircles the proximal portion of the urethra. In young animals, the prostate lies entirely within the pelvic cavity, but with sexual maturity it increases in size and assumes an abdominal position. Histologically, the prostate has an epithelial and a stromal component. The epithelial cells form tubuloalveoli that drain into the urethra. The prostate is surrounded by a capsule containing smooth muscle fibres that extend into the organ, dividing the alveolar tissue into dis tinct lobules. Blood supply to the prostate is supplied by the prostatic artery, which arises from the pudendal or umbilical artery. Anastomoses can be found between the prostatic vessels and the urethral artery, and the cranial and caudal rectal artery. Venous blood returns via the prostatic vein to the internal iliac vein. Lymph drains into the iliac lymph nodes. Sympathetic innervation is provided by the hypogastric nerve, which stimulates the active secretory process and expulsion of secretions by smooth muscle contractions. Parasympathetic innervation with fibres from the pelvic nerve also contributes to smooth muscle contraction1. 1 / 5 Fluid secreted by the prostate forms more than 90 per cent of the total volume of the ejaculate2 and is expulsed in the first and third fractions of the ejaculate.
    [Show full text]
  • The Use of Supercritical Fluid Extraction for the Determination of Steroids in Animal Tissues
    The use of supercritical fluid extraction for the determination of steroids in animal tissues Alida A. M. Stolker,* Paulus W. Zoontjes and Leendert A. van Ginkel a National Institute of Public Health and the Environment, Laboratory for Residue Analysis, PO Box 1, 3720 BA Bilthoven, The Netherlands Received 2nd July 1998, Accepted 2nd October 1998 A multi-analyte, multi-matrix method was developed for the routine determination of steroids in animal tissues (skin, meat and fat). After addition of internal standards and sample pre-treatment, the analytes of interest were extracted from the matrix with unmodified supercritical CO2 and trapped directly on an alumina sorbent placed in the extraction vessel (in-line trapping under supercritical conditions). After extraction, alkaline hydrolysis was performed and the analytes were derivatised. The samples were then analysed by gas chromatography-mass spectrometry. The limit of detection for the different matrix–analyte combinations was 2 mg kg21 (for melengestrol acetate 5 mg kg21), the repeatability ranged from 4 to 42% (n = 9) and the reproducibility ranged from 2 to 39% (n = 3). Introduction detection. By freeze-drying the samples of tissue before the SFE, this problem can be overcome. Throughout the European Union, the use of anabolic steroids is By choosing the right combination of freeze-drying, SFE and prohibited in food producing animals. Analytical methods SPE (Fig. 2), a multi-extraction technique has become available based on liquid–liquid extraction (LLE), solid phase extraction which can be used in routine residue determinations of steroids (SPE), high performance liquid chromatography (HPLC) and in samples of animal tissues such as meat, skin and fat.
    [Show full text]
  • Residues of Medroxyprogesterone Acetate Detected in Sows at A
    This article was downloaded by: [Cirad-Dist Bib Lavalette] On: 22 November 2013, At: 10:04 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK Food Additives & Contaminants: Part A Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/tfac20 Residues of medroxyprogesterone acetate detected in sows at a slaughterhouse, Madagascar Vincent Porphyrea, Michel Rakotoharinomeb, Tantely Randriamparanyc, Damien Pognona, Stéphanie Prévostd & Bruno Le Bizecd a Centre de Coopération Internationale en Recherche Agronomique pour le Développement – CIRAD, Réunion, France b Direction of Veterinary Services, Ministry of Livestock Production, Antananarivo, Madagascar c National Laboratory of Veterinary Diagnostic, Antananarivo, Madagascar d Laboratoire d’Etude des Résidus et Contaminants dans les Aliments (LABERCA), Ecole Nationale Vétérinaire, Agroalimentaire et de l’Alimentation Nantes Atlantique (ONIRIS), Nantes, France Accepted author version posted online: 24 Sep 2013.Published online: 20 Nov 2013. To cite this article: Vincent Porphyre, Michel Rakotoharinome, Tantely Randriamparany, Damien Pognon, Stéphanie Prévost & Bruno Le Bizec , Food Additives & Contaminants: Part A (2013): Residues of medroxyprogesterone acetate detected in sows at a slaughterhouse, Madagascar, Food Additives & Contaminants: Part A, DOI: 10.1080/19440049.2013.848293 To link to this article: http://dx.doi.org/10.1080/19440049.2013.848293 PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content.
    [Show full text]
  • Summary of Product Characteristics 1. Name Of
    Issued: April 2016 AN: 01740/2014 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tardastrex 10 mg/ml Suspension for Injection for Dogs and Cats [UK] Tardak 10 mg/ml Suspension for Injection for Dogs and Cats [CZ, HR, HU, PL, SI, SK] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance Delmadinone Acetate 10.0 mg Excipients Benzalkonium Chloride 0.2 mg Disodium edetate 1.0 mg For the full list of excipients, see Section 6.1 3. PHARMACEUTICAL FORM Suspension for injection. White suspension 4. CLINICAL PARTICULARS 4.1 Target species Dogs and cats. 4.2 Indications for use, specifying the target species The product is for use in male dogs and cats in the following indications: The treatment of hypersexuality (excessive or aberrant sexual behavior, including vagrancy) not related to sociopathic disorders. The relief of prostatic hypertrophy whether benign, carcinomatous or when due to chronic inflammatory processes (in cases of the latter, relief cannot be expected unless appropriate accompanying therapy, such as corticosteroids or antibiotics is also instituted). For the treatment of circum-anal tumours. For the treatment of certain forms of aggressiveness, nervousness, epileptiform seizures and corticosteroid-resistant pruritus (developing into dermatoses and accompanied by alopecia). Page 1 of 5 Issued: April 2016 AN: 01740/2014 4.3 Contraindications Do not use in patients with diabetes mellitus, severe impairment of liver and kidney function, mammary tumors. Do not use in patients receiving long term treatment with glucocorticoids or in dogs already receiving progestogens. Do not use in male dogs under one year.
    [Show full text]
  • Canine Prostate Disease
    Canine Prostate Disease Bruce W. Christensen, DVM, MS KEYWORDS Prostate Benign prostatic hyperplasia (BPH) Prostatitis Prostatic neoplasia Canine prostate-specific arginine esterase (CPSE) KEY POINTS All intact, male dogs eventually develop benign prostatic hyperplasia and a subset will develop clinical signs associated with subfertility, discomfort, or infection. Any male dog may develop neoplasia associated with the prostate, with a higher propor- tion of neutered males being affected. Ultrasound imaging and prostatic tissue cytology remain the most reliable diagnostic tests for canine prostate disease, but canine prostate-specific arginine esterase shows value as a supporting diagnostic test. Older recommendations to treat prostatitis for 4 to 8 weeks with appropriate antibiotics have been updated to now recommend a truncated 4-week treatment regime for acute cases. Medical treatments for benign prostatic hyperplasia have variable effects on prostate size and function, and may affect androgen production. Video content accompanies this article at http://www.vetsmall.theclinics.com/. INTRODUCTION The prostate is the only accessory sex organ in dogs. Diseases of the canine prostate are relatively common. The canine prostate is constantly developing and growing un- der androgenic influence throughout the life of the intact male dog. This androgenic influence seems to have a protective effect in the case of neoplastic disease,1–3 but the increase in size under androgens also predisposes the canine prostate to infection and cystic disease.4–6 The consequences of these diseases range from mild discom- fort to varying effects on semen quality to very painful or life-threatening illness. An evolving understanding of the way the canine prostate functions has led to expanded diagnostic options and recent changes in treatment recommendations for some of these conditions.
    [Show full text]
  • Page 1 FINLANDS FÖRFATTNINGSSAMLING Utgiven I Helsingfors
    FINLANDS FÖRFATTNINGSSAMLING MuuMnrovvvvBeslutom läkemedelsförteckning asia av Säkerhets- och utvecklingscentret för läkemedelsområdet Utgiven i Helsingfors den 23 mars 2016 201/2016 Beslut av Säkerhets- och utvecklingscentret för läkemedelsområdet om läkemedelsförteckning Säkerhets- och utvecklingscentret för läkemedelsområdet har med stöd av 83 § i läke- medelslagen av den 10 april 1987 (395/1987) beslutat fastställa följande läkemedelsför- teckning: 1§ Förteckningens syfte Föreliggande beslut innehåller en förteckning över ämnen och droger som används medicinskt i Finland. Läkemedelsförteckningen upprättas med beaktande av bestämmel- serna i 3 och 5 § i läkemedelslagen. Med läkemedel avses ett preparat eller ämne vars ändamål är att vid invärtes eller ut- värtes bruk bota, lindra eller förebygga sjukdomar eller sjukdomssymtom hos människor eller djur. Som läkemedel betraktas också ett sådant ämne eller en sådan kombination av ämnen för invärtes eller utvärtes bruk som kan användas för att genom farmakologisk, im- munologisk eller metabolisk verkan återställa, korrigera eller modifiera fysiologiska funk- tioner eller utröna hälsotillståndet eller sjukdomsorsaker hos människor eller djur. Läkemedelsförteckningen är inte uttömmande. Till läkemedel räknas även sådana äm- nen och droger som inte nämns i denna förteckning men som uppfyller definitionen av lä- kemedel i läkemedelslagen. Utöver fastställande av läkemedelsförteckningen beslutar Säkerhets- och utvecklings- centret för läkemedelsområdet med stöd av 6 § i läkemedelslagen vid behov om ett ämne eller ett preparat ska betraktas som ett läkemedel. Centret beslutar separat i respektive fall om ett preparat som innehåller ett ämne i förteckningen ska betraktas som ett läkemedel med beaktande av produktens framställningssätt, sammansättning, dess farmakologiska egenskaper, hur det används, dess spridning, hur känt det är hos konsumenterna och de ris- ker som kan vara förenade med dess användning.
    [Show full text]